Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 31

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 31
---
 or audit all such data (including possibly material portions thereof), and therefore, any such potential future data may be inaccurate,
misleading, or incomplete.

Risks Related to Intellectual
Property 

If we are able to raise sufficient capital and
potentially license or acquire new technologies, we may be unable to obtain and maintain intellectual property protection for these technologies
or products we plan to license or develop or if the scope of the intellectual property protection obtained is not sufficiently broad,
our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully
commercialize our technology and products may be impaired. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then our success depends in large part on our ability to obtain and maintain patent protection in
the United States, the European Union, and other countries with respect to proprietary technology and products we plan to develop. We
will seek to protect our proprietary position by filing patent applications in the United States and internationally that are related
to novel technologies and product candidates.

 18 

The patent prosecution process is expensive and time-consuming,
and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.
We may choose not to seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions,
and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. It
is also possible that we will fail to identify patentable aspects of our discovery and preclinical development output before it is too
late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution
of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and
applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much
litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United
States and other jurisdictions are typically not published until 18 months after filing, or in limited cases not at all. Therefore, we
cannot know with certainty whether